Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs

New oral approach aimed at disrupting cancer metabolismSM-88 is an investigational Cancer Metabolism-Based Therapy (CMBTsTM) that has demonstrated responses across 15 different cancers30 patients...
April 03, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced the closing...
April 01, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Dismissal of Class Action Lawsuit

NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) announced the...
March 29, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies Announces Pricing of its $12 Million Registered Offering

NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value...
March 18, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Leadership Team Update

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, announced a realignment in...
March 11, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies To Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that management will...
March 07, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Continues to Expand Pipeline of Cancer Metabolism-Based Therapies to Potentially Benefit Patients with Difficult-to-Treat Cancers

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced the addition of...
February 25, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design...
February 14, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer

SM-88 therapy did not exhibit typical side effects associated with hormonal castration from androgen-deprivation therapy (ADT)87% of patients (20/23) remained free of radiographic progressionAfter 12...
February 11, 2019 07:30 ET | Source: Tyme Technologies, Inc.

TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results

TYME’s novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients...